A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection

NCT04856761 · clinicaltrials.gov ↗

UNKNOWN

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Neoplasms
Recurrence
Cholangiocarcinoma
Gall Bladder Cancer

Interventions

DRUG: S-1
DRUG: Capecitabine

Sponsor

Fudan University